Source:http://linkedlifedata.com/resource/pubmed/id/16142373
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2005-9-5
|
| pubmed:abstractText |
E-cadherin is a transmembrane glycoprotein involved in intercellular adhesion. Abnormal (i.e., lost or decreased) expression of E-cadherin has been linked to invasiveness of many malignant tumors, including bladder carcinomas. To our knowledge, studies analyzing the prognostic impact of E-cadherin immunoreactivity especially in minimally invasive transitional cell bladder carcinomas (stage pT1) have not been published in the Anglo-American literature. In the present study, we immunostained 69 cases of pT1 transitional cell bladder carcinomas for E-cadherin using multitissue arrays. The results were compared with p53 and Ki-67 antigen immunoreactivity, clinicopathological parameters and the patients' outcome. E-cadherin immunoreactivity, which was found abnormal in 42% of cases, correlated significantly with substage (pT1a/pT1b; p=0.029) and p53 index (p=0.041) and tendentiously with Ki-67 antigen index (p=0.089) and age (p=0.07). By univariate Cox regression analysis, abnormal E-cadherin immunostaining correlated significantly (p=0.005) with early tumor recurrence, but not with early tumor progression (p=0.168). In a multivariate analysis, this parameter was identified, besides tumor grade (p=0.002), as an independent predictor of recurrence-free survival (p=0.016). Concerning tumor progression, age was identified as the single independent prognostic parameter (p=0.041), but E-cadherin immunoreactivity displayed a tendentious independent predictive value in this respect (p=0.071). We conclude from our data that immunohistochemical E-cadherin staining may provide additional prognostic information in patients with pT1 bladder carcinomas.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1021-335X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
14
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1065-70
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16142373-Aged,
pubmed-meshheading:16142373-Antigens, Neoplasm,
pubmed-meshheading:16142373-Cadherins,
pubmed-meshheading:16142373-Carcinoma, Transitional Cell,
pubmed-meshheading:16142373-Cohort Studies,
pubmed-meshheading:16142373-Cytoplasm,
pubmed-meshheading:16142373-Disease Progression,
pubmed-meshheading:16142373-Disease-Free Survival,
pubmed-meshheading:16142373-Female,
pubmed-meshheading:16142373-Humans,
pubmed-meshheading:16142373-Immunohistochemistry,
pubmed-meshheading:16142373-Ki-67 Antigen,
pubmed-meshheading:16142373-Male,
pubmed-meshheading:16142373-Middle Aged,
pubmed-meshheading:16142373-Multivariate Analysis,
pubmed-meshheading:16142373-Prognosis,
pubmed-meshheading:16142373-Proportional Hazards Models,
pubmed-meshheading:16142373-Recurrence,
pubmed-meshheading:16142373-Time Factors,
pubmed-meshheading:16142373-Tumor Suppressor Protein p53,
pubmed-meshheading:16142373-Urinary Bladder Neoplasms
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
|
| pubmed:affiliation |
Institute of Pathology, University of Schleswig-Holstein (Campus Lübeck), Ratzeburger Allee 160, D-23538 Lübeck, Germany.
|
| pubmed:publicationType |
Journal Article
|